Citations

Clear

1446 citation(s) found for "Howard, F".

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Casulo, Carla , Dixon, Jesse G. , Le‐Rademacher, Jennifer , Hoster, Eva , Höchster, Howard S. , Marcus, Robert, Herold, Michael , Sebban, Catherine, Foon, Kenneth A. , Nielsen, Tina, Vitolo, Umberto , Shi, Qian , Flowers, Christopher R. , Gyan, Emmanuel , Vitolo, Umberto , Salles, Gilles A , Le-Rademacher, Jennifer G , Shi, Qian , Casulo, Carla , Hoster, Eva , Dixon, Jesse G , Klapper, Wolfram , Marcus, Robert, Kimby, Eva , Gyan, Emmanuel , Salles, Gilles

Mayo Clinic

Blood | March 17, 2022 | Volume: 139 | Issue: 11 | Pages: 1684-1693

10.1182/blood.2020010263 | PMID 34614146 Get It

Abstract Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable performance status (PS), limited-stage (I/II) disease, low-risk FL International Prognostic Index (FLIPI) score, normal baseline hemoglobin, and normal baseline β2 microglobulin (B2M) level. In a multivariable logistic regression model, male sex (odds ratio [OR], 1.30), PS ≥2 (OR, 1.63), B2M (≥3 mg/L; OR, 1.43), and high-risk FLIPI score (3-5; OR, 3.14) were associated with increased risk of progression before 24 months. In the time-dependent Cox model and the 24-month landmark analysis, POD24 was associated with poor subsequent OS (hazard ratio, 4.85 and 3.06, respectively). This is the largest pooled analysis of clinical trials data validating POD24 as a robust indicator of poor FL survival and identified clinical predictors of early death and progression that can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.
Characteristics of Post-ICU and Post-COVID Recovery Clinics in 29 U.S. Health Systems
Danesh, Valerie, Boehm, Leanne M., Eaton, Tammy L., Arroliga, Alejandro C., Mayer, Kirby P., Kesler, Shelli R., Bakhru, Rita N., Baram, Michael, Bellinghausen, Amy L., Biehl, Michelle, Dangayach, Neha S., Goldstein, Nir M., Hoehn, K. Sarah, Islam, Marjan, Jagpal, Sugeet, Johnson, Annie B., Jolley, Sarah E., Kloos, Janet A., Mahoney, Eric J., Maley, Jason H., Martin, Sara F., McSparron, Jakob I., Mery, Marissa, Saft, Howard, Santhosh, Lekshmi, Schwab, Kristin, Villalba, Dario, Sevin, Carla M., Montgomery, Ashley A., Boehm, Leanne M. , Eaton, Tammy L. , Santhosh, Lekshmi , Danesh, Valerie , Mayer, Kirby P. , Arroliga, Alejandro C., Mayer, Kirby P., Kesler, Shelli R., Bakhru, Rita N., Baram, Michael, Bellinghausen, Amy L., Biehl, Michelle, Dangayach, Neha S., Goldstein, Nir M., Hoehn, K. Sarah, Islam, Marjan, Jagpal, Sugeet, Johnson, Annie B., Jolley, Sarah E., Kloos, Janet A., Mahoney, Eric J., Maley, Jason H., Martin, Sara F., McSparron, Jakob I., Mery, Marissa , Saft, Howard, Schwab, Kristin, Villalba, Darío Salvador , Sevin, Carla M., Montgomery, Ashley A.

Mayo Clinic

Critical Care Explorations | March 9, 2022 | Volume: 4 | Issue: 3 | Pages: e0658

10.1097/cce.0000000000000658 | PMID 35291316 Get It

OBJECTIVES: The multifaceted long-term impairments resulting from critical illness and COVID-19 require interdisciplinary management approaches in the recovery phase of illness. Operational insights into the structure and process of recovery clinics (RCs) from heterogeneous health systems are needed. This study describes the structure and process characteristics of existing and newly implemented ICU-RCs and COVID-RCs in a subset of large health systems in the United States. DESIGN: Cross-sectional survey. SETTING: Thirty-nine RCs, representing a combined 156 hospitals within 29 health systems participated. PATIENTS: None. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: RC demographics, referral criteria, and operating characteristics were collected, including measures used to assess physical, psychologic, and cognitive recoveries. Thirty-nine RC surveys were completed (94% response rate). ICU-RC teams included physicians, pharmacists, social workers, physical therapists, and advanced practice providers. Funding sources for ICU-RCs included clinical billing (n = 20, 77%), volunteer staff support (n = 15, 58%), institutional staff/space support (n = 13, 46%), and grant or foundation funding (n = 3, 12%). Forty-six percent of RCs report patient visit durations of 1 hour or longer. ICU-RC teams reported use of validated scales to assess psychologic recovery (93%), physical recovery (89%), and cognitive recovery (86%) more often in standard visits compared with COVID-RC teams (psychologic, 54%; physical, 69%; and cognitive, 46%). CONCLUSIONS: Operating structures of RCs vary, though almost all describe modest capacity and reliance on volunteerism and discretionary institutional support. ICU- and COVID-RCs in the United States employ varied funding sources and endorse different assessment measures during visits to guide care coordination. Common features include integration of ICU clinicians, interdisciplinary approach, and focus on severe critical illness. The heterogeneity in RC structures and processes contributes to future research on the optimal structure and process to achieve the best postintensive care syndrome and postacute sequelae of COVID outcomes.
Ptf1a Promoter-Driven Cre Expression During Spermatogenesis Causes Germline Recombination
Wang, Jiale, Wang, Oliver, Bi, Yan, Wang, Ying, Crawford, Howard, Ji, Baoan, Wang, Jiale , Wang, Jiale , Wang, Jiale, Wang, Oliver, Bi, Yan, Wang, Ying, Crawford, Howard, Ji, Baoan

Mayo Clinic

Pancreas | February 23, 2022 | Volume: 51 | Issue: 1 | Pages: 90-93

10.1097/mpa.0000000000001961 | PMID 35195600 Get It

Objectives Two independently developed Ptf1a-Cre mouse lines, Ptf1atm1(cre)Hnak and Ptf1atm1(Cre)Cvw, are widely used in pancreatic research. Recently, Ptf1atm1(cre)Hnak line was reported to transmit unwanted paternal recombination. We aimed to investigate whether this exists in the Ptf1atm1(Cre)Cvw line. Methods Ptf1atm1(Cre)Cvw mice were crossed with R26-LSL-LacZ reporter mice. DNA recombination and gene expression were examined by recombination-specific polymerase chain reaction, reverse transcription–polymerase chain reaction, and X-Gal staining. Results R26 locus recombination was detected in the pancreas as well as the testes and sperm of the double transgenic mice. Positive ptf1a mRNA expression from testes revealed that there was endogenous Ptf1a promoter activity in this extrapancreatic tissue. Of the 15 progenies that inherited LacZ from the male double transgenic mice, 4 (26.7%) were positive for complete whole-body recombination. The presence of recombination in R26 only mice suggested that the recombination occurred before meiosis. Conclusions Paternal germline recombination exists in the Ptf1atm1(Cre)Cvw mouse line. Ptf1a promoter-driven Cre expression during spermatogenesis before meiosis is the cause of germline recombination. Therefore, when male Ptf1a-Cre mice are used in compound mice breeding, it is necessary to genotype not only floxed alleles but also recombined alleles to examine unwanted recombinations.
Social Isolation and Incident Heart Failure Hospitalization in Older Women: Women’s Health Initiative Study Findings
Cené, Crystal W. , Leng, Xiaoyan , Faraz, Khushnood , Allison, Matthew , Breathett, Khadijah , Bird, Chloe E. , Coday, Mace , Corbie‐Smith, Giselle , Foraker, Randi E. , Ijioma, Nkechinyere , Rosal, Milagros C. , Sealy–Jefferson, Shawnita , Shippee, Tetyana , Rossouw, Jacques E. , Ludlam, Shari, McGowan, Joan, Ford, Leslie, Geller, Nancy L. , Prentice, Ross, LaCroix, Andrea Z. , Kooperberg, Charles, Howard, Barbara V. , Jackson, Rebecca D. , Thomson, Cynthia A. , Limacher, Marian C. , Robinson, Jennifer G., Kuller, Lewis, Shumaker, Sally A., Brunner, Robert L. , Bird, Chloe , Foraker, Randi , Ijioma, Nkechinyere N, Kroenke, Candyce H , Ijioma, Nkechi , Breathett, Khadijah , Allison, Matthew A , Anderson, Garnet L. , Manson, JoAnn E. , Stefanick, Marcia L , Wactawski‐Wende, Jean

Mayo Clinic

Journal of the American Heart Association | February 22, 2022 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/jaha.120.022907 | PMID 35189692 Get It

Background The association of social isolation or lack of social network ties in older adults is unknown. This knowledge gap is important since the risk of heart failure (HF) and social isolation increase with age. The study examines whether social isolation is associated with incident HF in older women, and examines depressive symptoms as a potential mediator and age and race and ethnicity as effect modifiers. Methods and Results This study included 44 174 postmenopausal women of diverse race and ethnicity from the WHI (Women's Health Initiative) study who underwent annual assessment for HF adjudication from baseline enrollment (1993–1998) through 2018. We conducted a mediation analysis to examine depressive symptoms as a potential mediator and further examined effect modification by age and race and ethnicity. Incident HF requiring hospitalization was the main outcome. Social isolation was a composite variable based on marital/partner status, religious ties, and community ties. Depressive symptoms were assessed using CES‐D (Center for Epidemiology Studies‐Depression). Over a median follow‐up of 15.0 years, we analyzed data from 36 457 women, and 2364 (6.5%) incident HF cases occurred; 2510 (6.9%) participants were socially isolated. In multivariable analyses adjusted for sociodemographic, behavioral, clinical, and general health/functioning; socially isolated women had a higher risk of incident HF than nonisolated women (HR, 1.23; 95% CI, 1.08–1.41). Adding depressive symptoms in the model did not change this association (HR, 1.22; 95% CI, 1.07–1.40). Neither race and ethnicity nor age moderated the association between social isolation and incident HF. Conclusions Socially isolated older women are at increased risk for developing HF, independent of traditional HF risk factors. Registration URL: http://www.clinicaltrials.gov ; Unique identifier: NCT00000611.
Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas
Brat, Daniel J., Aldape, Kenneth, Bridge, Julia A., Canoll, Peter, Colman, Howard, Hameed, Meera R., Harris, Brent T., Hattab, Eyas M., Huse, Jason T., Jenkins, Robert B., Lopez-Terrada, Dolores H., McDonald, William C., Rodriguez, Fausto J., Souter, Lesley H., Colasacco, Carol, Thomas, Nicole E., Yount, Michelle Hawks, Bent, Martin J. van den, Perry, Arie, Bent, Martin J. van den , Colasacco, Carol , van den Bent, Martin J , Brat, Daniel J., Aldape, Kenneth, Bridge, Julia A., Canoll, Peter, Colman, Howard, Hameed, Meera R., Harris, Brent T., Hattab, Eyas M. , Huse, Jason T., Jenkins, Robert B., Lopez-Terrada, Dolores H., McDonald, William C., Rodriguez, Fausto J., Souter, Lesley H., Colasacco, Carol, Thomas, Nicole E., Yount, Michelle Hawks, Perry, Arie

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 17, 2022 | Volume: 146 | Issue: 5 | Pages: 547-574

10.5858/arpa.2021-0295-cp | PMID 35175291 Get It

Context.— The diagnosis and clinical management of patients with diffuse gliomas (DGs) have evolved rapidly over the past decade with the emergence of molecular biomarkers that are used to classify, stratify risk, and predict treatment response for optimal clinical care. Objective.— To develop evidence-based recommendations for informing molecular biomarker testing for pediatric and adult patients with DGs and provide guidance for appropriate laboratory test and biomarker selection for optimal diagnosis, risk stratification, and prediction. Design.— The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. A systematic review of literature was conducted to address the overarching question, “What ancillary tests are needed to classify DGs and sufficiently inform the clinical management of patients?” Recommendations were derived from quality of evidence, open comment feedback, and expert panel consensus. Results.— Thirteen recommendations and 3 good practice statements were established to guide pathologists and treating physicians on the most appropriate methods and molecular biomarkers to include in laboratory testing to inform clinical management of patients with DGs. Conclusions.— Evidence-based incorporation of laboratory results from molecular biomarker testing into integrated diagnoses of DGs provides reproducible and clinically meaningful information for patient management.
Local failure, distant metastasis, and survival after definitive radiotherapy for intermediate- and high-risk prostate cancer: An individual patient-level meta-analysis of 18 randomized trials.
Martin, Ting , Chu, Fang‐I, Romero, Tahmineh , Michalski, Jeff M. , Pisansky, Thomas M. , Roach, Mack , Feng, Felix Y. , Bolla, M. , Sydes, Matthew R. , Nabid, Abdenour , Steigler, Allison , Souhami, Luís, Armstrong, John, Malone, Shawn , Kishan, Amar U. , Ma, Ting Martin , Sandler, Howard M. , Neven, Anouk , Incrocci, Luca , Denham, James William , Spratt, Daniel E.

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 277-277

10.1200/jco.2022.40.6_suppl.277 Get It

277 Background: The prognostic importance of local failure (LF) after definitive radiotherapy (RT) in patients with NCCN intermediate- (IRPCa) and high-risk prostate cancer (HRPCa) remains unclear, particularly given the likelihood that occult distant metastases (DMs) at presentation may be the true driver of natural history. Here, we leverage individual patient data (IPD) from 18 randomized control trials (RCTs) to evaluate the prognostic impact of LF and the kinetics of DM after RT. Methods: IPD for 18 RCTs were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate (MARCAP) Consortium, comprising a total of 12533 patients (6288 HRPCa & 6245 IRPCa). Multivariable Cox proportional hazards (PH) models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), DM-free survival (DMFS) & LF as a time-dependent covariate, adjusted for clinicodemographic parameters. Markov PH models, defined via transitions between 4 states, were developed to evaluate the aforementioned relationship. Proportional hazards assumption was imposed and examined for both models. Time is from randomization. Results: Median follow-up was 9.1 years. There were 795 (13%) LF & 1288 (21%) DM events for patients with HRPCa; these numbers were 449 (7%) & 451 (7%) for IRPCa. For HRPCa & IRPCa, 81% and 81% of DMs developed from a clinically relapse-free state (cRFS), with a median time of 46 and 60 months, respectively (p < 0.0001). 39% & 13% of DM events occurred within 2 years after RT for HRPCa & IRPCa, respectively. At later time points, DM events were more likely to emerge after an LF event for both HRPCa (9% vs. 34% between 0-2 vs. 8-10 years post-RT, p = 0.001) and IRPCa (10% vs. 34% between 0-2 vs. 8-10 years post-RT, p = 0.008). LF was significantly associated with OS (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.06–1.30), PCSS (HR 2.02, 95% CI 1.75-2.33) & DMFS (HR 1.94, 95% CI 1.75–2.15) (p < 0.01 for all) in patients with HRPCa. LF was also significantly associated with DMFS (HR 1.57, 95% CI 1.36–1.81) but not OS in patients with IRPCa. Patients who had not transitioned to the LF state had a significantly lower HR of transitioning to a PCa-specific death state than those who transitioned to the LF state (HR 0.32, 95% CI 0.21–0.50, p < 0.001). Conclusions: LF is an independent prognosticator of OS, PCSS & DMFS in HRPCa and of DMFS in IRPCa. The predominant mode of DM development is from the cRFS state, underscoring the importance of accurate upfront staging & systemic therapy. However, particularly at late time points, an increasing proportion of DM events originated after diagnosis of a LF, constituting a “second wave” of DM events. This suggests that optimizing local control is also important, though the majority of DM events appear prior to a clinically-detected LF.
Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601.
Chan, Emily , Pugh, Stephanie L. , Simko, Jeff, Feng, Felix Y. , Shipley, William U. , Lukka, Himanshu, Bahary, Jean-Paul , Pisansky, Thomas M. , Zeitzer, Kenneth L. , Lawton, C.A., Balogh, Alexander G., Lovett, R.D., Wong, Anthony , Dess, Robert T. , McGinnis, Scott, Kuettel, Michael, DeMora, Lyudmila, Dess, Robert T , Efstathiou, Jason A. , Rosenthal, Seth A. , McGinnis, Scott, Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 265-265

10.1200/jco.2022.40.6_suppl.265 Get It

265 Background: A recent study ( Fossati et al, 2018) found that higher lymph node count at radical prostatectomy was associated with improved outcomes in patients treated with salvage radiation for elevated prostate-specific antigen (PSA) after surgery. We sought to validate these results in NRG/RTOG 9601, a randomized controlled trial of men with pT2/T3 disease who underwent either radiation (RT) alone or RT+antiandrogen (bicalutamide) therapy for PSA elevation following radical prostatectomy from 1998-2003. Methods: We reviewed available pathology reports for all patients in NRG/RTOG 9601 to determine the nodal count at radical prostatectomy. Clinical data was as of 11/5/2015, same as the primary endpoint for the trial. Cox proportional hazards models were used to assess the effect of number of positive lymph nodes, treatment arm (RT alone or RT+bicalutamide), Gleason score, positive margins, and seminal vesicle invasion on the following endpoints: times to local and distant failure and overall and disease specific survival. Results: Out of the 760 patients originally eligible in the trial, 552 (73%, 276 in each arm) had complete data available. Median node count in the entire cohort was 6 (range 0-33, Q1-Q3 3-9). There were no significant differences between treatment arms in terms of patient demographic or clinical characteristics, including total lymph nodes removed in either arm (RT alone vs RT+bicalutamide median 5 vs 6, p = 0.11). There was no significant association between total lymph nodes and overall survival with both arms combined (HR = 1.00, 95% CI:0.97-1.03, p = 0.87) or in the individual arms alone (RT+Casodex: HR = 1.01, 95% CI:0.97-1.05, p = 0.65; RT+Placebo: HR = 0.98, 95% CI: 0.94-1.03, p = 0.45). There was also no significant association between total lymph nodes and disease-specific survival with both arms combined (HR = 1.00, 95% CI:0.95-1.04, p = 0.84) and in the arms alone (RT+Casodex: HR = 1.00, 95% CI:0.95-1.05, p = 0.92; RT+Placebo: HR = 0.99, 95% CI: 0.92-1.07, p = 0.86). In multivariable analysis performed on the two arms, Gleason score was the only feature associated with worse overall and disease-specific survival, seen only in the RT alone arm. Similar findings were seen when evaluating times to local and distant failure. Conclusions: Lymph node yield in NRG/RTOG 9601 did not show any association with adverse outcomes in the entire cohort, or in either treatment arm alone. The therapeutic benefit of an extensive lymph node dissection in this population remains uncertain. Clinical trial information: NCT00002874.
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution
Chiu, April , Dasari, Surendra , Kurtin, Paul J. , Theis, Jason D. , Vrana, Julie A. , Dao, Linda N. , Howard, Matthew T., Grogan, Martha , Dispenzieri, Angela , McPhail, Ellen Darcy , Dispenzieri, Angela , Rech, Karen L.

Mayo Clinic

Amyloid | February 9, 2022 | Volume: 29 | Issue: 3 | Pages: 156-164

10.1080/13506129.2022.2031963 | PMID 35135386 Get It

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies
Odia, Yazmín , Cavalcante, Ludimila , Safran, Howard , Powell, Steven , Carneiro, Benedito A. , Bastos, Bruno R. , Mikrut, Stacy, Mikrut, William , Sahebjam, Solmaz , Odia, Yazmin , Münster, Pamela N. , Wee, Wen , Giles, Francis Joseph

Mayo Clinic

Neuro-Oncology Advances | February 9, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac012 | PMID 35402914 Get It

Abstract Background GSK3β serine/threonine kinase regulates metabolism and glycogen biosynthesis. GSK3β overexpression promotes progression and resistance through NF-κB and p53 apoptotic pathways. GSK3β inhibits immunomodulation by downregulating PD-L1 and LAG-3 checkpoints and increasing NK and T-cell tumor killing. 9-ING-41, a small-molecule, selective GSK3β inhibitor, showed preclinical activity in chemo-resistant PDX glioblastoma models, including enhanced lomustine antitumor effect. Methods Refractory malignancies (n = 162) were treated with 9-ING-41 monotherapy (n = 65) or combined with 8 cytotoxic regimens after prior exposure (NCT03678883). Recurrent gliomas (n = 18) were treated with 9-ING-41 IV TIW q21day cycles at 3.3, 5, 9.3, 15 mg/kg, as monotherapy or combined with lomustine 30 mg/m² PO weekly q84day cycles. Primary objective was safety. Results RP2D of 15 mg/kg IV TIW was confirmed across all 9 regimens, no accentuated chemotherapy toxicity noted. Glioma subtypes included: 13 glioblastoma, 2 anaplastic astrocytomas, 1 anaplastic oligodendroglioma, 1 astrocytoma. Median age 52 (30–69) years; 6 female, 12 male; median ECOG 1 (0–2); median recurrences 3 (1–6). All received upfront radiation/temozolomide (18/18), plus salvage nitrosoureas (15/18), bevacizumab (8/18), TTFields (6/18), or immunotherapy (4/18). IDH/mutation(3/18); 1p19q/codeletion(1/18); MGMT/methylated(1/18). Four received 9-ING-41 monotherapy, 14 concurrent with lomustine. No severe toxicities were attributed to 9-ING-41, only mild vision changes (9/18, 50%), or infusion reactions (4/18, 22%). Lomustine-related toxicities: G3/4 thrombocytopenia (3/14, 21%), G1/2 fatigue (4/14, 28%). Median days on therapy was 55 (4–305); 1 partial response (&gt;50%) was noted. Median OS was 5.5 (95% CI: 2.8–11.4) months and PFS-6 was 16.7%. Conclusion 9-ING-41 plus/minus lomustine is safe and warrants further study in glioma patients.